Canaccord Lowers Targets On Numerous Top Level Cannabis Equities

On February 4th, Canaccord Genuity came out with their cannabis fourth quarter 2021 preview. On that note, they lowered almost every single 12-month price target in their cannabis coverage.

  • Ayr Wellness (CSE: AYR.a) price target was lowered to C$57 from C$62
  • Columbia Care’s (CSE: CCHW) was lowered to C$11 from C$13
  • Cresco Labs (CSE: CL) lowered to C$15 from C$16
  • Curaleaf (CSE: CURA) was dropped from C$22 down to C$18
  • Green Thumb’s (CSE: GTII) lowered to C$46 from C$53
  • Trulieve’s (CSE: TRUL) lowered from C$97 to C$70.

Canaccord says that through their channel checks, they expect a more subdued end to the year with fourth-quarter revenues coming in flatter than at any point in 2021. They believe that this is primarily a function of record-high inflation, making consumers spend more on their other living expenses such as groceries and gas.

Additionally, after speaking to many U.S operators, many have noted that there is a wholesale pricing issue that is expected to continue into 2022 as more capacity continues to come online.

Even with this issue potentially hitting the companies margins, Canaccord expects 2022 to still be a banner year for the sector. They believe that the sector could hit the coveted US$30 billion run rate this year. They add that having exposure to the US cannabis sector currently is a “compelling valuation proposition.”

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Lastly, Canaccord believes that the >60% drawdown in the USMJ names seen in the last year comes from “structural challenges in the equity markets given that cannabis remains an illicit Schedule 1 drug at the federal level.” Rather than any sort of concerns around the operational side of the businesses.

Below you can see Canaccord’s fourth-quarter earnings previews.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Red Cloud Fall Mining Showcase 2026 | Day 2

More Gold Without a Bigger Upfront Bill? | Keith Boyle – New Found Gold

The Red Cloud Fall Mining Showcase 2026 | Day 1

Recommended

First Majestic Hits 4.24 g/t Gold Over 48.8 Metres at Saval as Jerritt Canyon Restart Advances

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Related News

Columbia Care: Analysts Expect $17.2 Million In Q2 EBITDA

Columbia Care Inc. (CSE: CCHW) announced that they will be reporting their second quarter financials...

Tuesday, August 10, 2021, 11:51:00 AM

Cronos Group: Canaccord Reiterates Sell Rating Follow Q4 2021 Results

Yesterday, Cronos Group (TSX: CRON) reported their fourth-quarter and full-year financial results. The company reported...

Wednesday, March 2, 2022, 03:42:00 PM

Medipharm Labs Sees Canaccord Drop Price Target To $0.75

On May 17th, MediPharm Labs (TSX: LABS) Labs reported their first-quarter financials. The company announced...

Tuesday, May 18, 2021, 05:32:00 PM

BMO: Netflix Is Now “Growth At A Reasonable Price”

The earnings season has started off with a bang as Netflix (Nasdaq: NFLX) closed its...

Wednesday, April 20, 2022, 04:45:47 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM